Podcasts about transplantation

In a live X Spaces discussion hosted by CancerNetwork® in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT), Marc J. Braunstein, MD, PhD, and Sofia Zahid, MD, highlighted noteworthy presentations and abstracts in hematologic oncology at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Together, they discussed the data that may shake up clinical practice across different multiple myeloma, leukemia, and lymphoma populations.

In a live X Spaces discussion hosted by CancerNetwork® in collaboration with the American Society for Transplantation and Cellular Therapy (ASTCT), Marc J. Braunstein, MD, PhD, and Sofia Zahid, MD, highlighted noteworthy presentations and abstracts in hematologic oncology at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Together, they discussed the data that may shake up clinical practice across different multiple myeloma, leukemia, and lymphoma populations.Braunstein is an associate professor in the Department of Medicine and course co-director of the Hematology/Oncology System at NYU Grossman Long Island School of Medicine, as well as the fellowship program director of Hematology/Oncology at NYU Langone Health. Zahid is a first-year fellow at NYU Grossman Long Island School of Medicine.The discussion focused on the following abstracts:·      Abstract 7512o   Combining belantamab mafodotin-blmf (Blenrep) with daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone produced rapid activity among patients with transplant-ineligible newly diagnosed multiple myeloma in the phase 1/2 BelaDRd study (EUCT-2024-515634-32).o   The progression-free survival (PFS) benefits observed in the trial support further evaluation of the quadruplet in a phase 3 study compared with other novel combination regimens in NDMM.·      Abstract 6505o   Revumenib (Revuforj) maintenance therapy after allogeneic stem cell transplantation showed feasibility in a heavily pretreated cohort of patients with acute myeloid leukemia (AML).o   Outcomes appeared favorable vs historical cohorts, supporting prospective assessment of maintenance menin inhibition among those with AML.·      Abstract 1503o   In a retrospective analysis of electronic medical records for 293 patients who received CAR T-cell therapy for lymphoma (n = 175), multiple myeloma (n = 106), or B-cell acute lymphoblastic leukemia (n = 12), outpatient monitoring was associated with significantly fewer hospital days without increased emergency department visits or 30-day mortality.o   These findings show the potential for lower healthcare utilization for patients who receive CAR T-cell therapy in the outpatient setting.·      Abstract LBA7000o   Adding tafasitamab (Monjuvi) and lenalidomide to rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) significantly improved PFS vs R-CHOP alone among those with newly diagnosed diffuse large B-cell lymphoma (DLBCL) in the phase 3 frontMIND trial (NCT04824092).o   The data may support tafasitamab plus lenalidomide and R-CHOP as a potential new standard of care in the frontline treatment of patients with cell-of-origin subtypes of high-risk DLBCL.References Terpos E, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. Belantamab mafodotin with daratumumab, lenalidomide, and dexamethasone in transplant-ineligible, newly diagnosed multiple myeloma patients: phase 1/2 BelaDRd study. J Clin Oncol. 2026;44(suppl 16):7512. doi:10.1200/JCO.2026.44.16_suppl.7512 Goulart H, Okeleji O, DiNardo CD, et al. Revumenib as maintenance for AML following allogeneic stem cell transplantation. J Clin Oncol. 2026;44(suppl 16):6505. doi:10.1200/JCO.2026.44.16_suppl.6505 Bowen SG, Abdallah N, Pritchett JC, et al. Impact of outpatient CAR T-cell therapy administration on healthcare utilization in patients with hematologic malignancies. J Clin Oncol. 2026;44(suppl 16):1503. doi:10.1200/JCO.2026.44.16_suppl.1503 Lenz, G, Trněný M, Burke JM, et al. frontMIND: phase 3 study of tafasitamab (Tafa) plus lenalidomide (Len) and R-CHOP for patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2026;44(suppl 17):LBA7000. doi:10.1200/JCO.2026.44.17_suppl.LBA7000

In Deutschland werden zu wenig Organe gespendet: Jeden Tag sterben durchschnittlich zwei bis drei Menschen, die auf der Warteliste für eine Transplantation stehen. Ein wesentlicher Grund liegt laut Experten in der restriktiven deutschen Gesetzgebung. Der Bundestag hat im Frühjahr eine Reform des Transplantationsgesetzes beschlossen und will damit Nierenspenden von lebenden Personen vereinfachen. NDR-Journalistin Antje Büll recherchiert seit Jahren zum Thema und erzählt in dieser 11KM-Folge, was sich mit der Reform ändert und was nicht. Antje Bülls Film für Arte Re “Meine Niere für einen Fremden” findet ihr hier: https://www.arte.tv/de/videos/127399-001-A/re-meine-niere-fuer-einen-fremden/ In dieser früheren 11KM-Folge geht es um häusliche Pflege in Deutschland – und den Kampf der Pflegenden um faire Bezahlung: https://1.ard.de/11KM_24h_Pflege Hier geht's zu “Seelenfänger - Holy Hell”, unserem Podcast-Tipp: https://1.ard.de/seelenfaenger7?cp=11km Diese und viele weitere Folgen von 11KM findet ihr überall da, wo es Podcasts gibt, auch hier in ARD Sounds: https://www.ardsounds.de/sendung/11km-der-tagesschau-podcast/urn:ard:show:4549910994dc2464/ An dieser Folge waren beteiligt: Folgenautor: Max Stockinger Mitarbeit: Lukas Waschbüsch, Marc Hoffmann Host: Elena Kuch Produktion: Fabien Zweck, Lorenz Kersten, Viktor Fölsner-Veress, Christine Dreyer und Marie-Noelle Svihla Planung: Laura Stuhlmacher, Nicole Dienemann und Hardy Funk Distribution: Kerstin Ammermann Redaktionsleitung: Yasemin Yüksel und Fumiko Lipp 11KM: der tagesschau-Podcast wird produziert von BR24 und NDR Info. Die redaktionelle Verantwortung für diese Episode liegt beim BR.

In a special cobranded episode between Oncology on the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, host Rahul Banerjee, MD, FACP, spoke with colleague Hitomi Hosoya, MD, PhD, about a study she and coauthors published in Blood. In their study, Hosoya and colleagues assessed the underlying mechanisms of chimeric antigen receptor (CAR) T-cell–related lymphomas developing in the gastrointestinal (GI) tract. The study focused on a particular case involving a 50-year-old patient with relapsed/refractory multiple myeloma who developed T-cell lymphoma after receiving cellular therapy in the seventh-line setting. Listen below or via your favorite podcast platform.

In this episode, Drs. Jason Silverman and Amber Hildreth talk to Dr. Valeria Cohran about the advances in intestinal rehabilitation care for infants and children with short bowel syndrome including changes nutrition management, line care and use of GLP-2 analogues that have led to decreases in intestinal failure associated liver disease and transplantation. Learning objectivesTo understand the composition and impact of multidisciplinary intestinal rehabilitation teams.To review the historical presentation of intestinal failure-associated liver disease (IFALD) and changes in practice that have reduced its prevalence and severity.To review GLP-2 analogues and their impact on outcomes and quality of life for children with short bowel syndrome. LinksPapers mentioned:PIFCON data paper on IFALDCholestasis and infection in long-term PNManagement of CVL in SBS Position PaperIntestinal Rehabilitation Teams Practice GuidelinePrevious episodes mentioned:Sue Protheroe - Enteral Nutrition in Intestinal FailureDanielle Wendel - Central Line Management in Intestinal Failure (Special JPGN Episode)Ruben Quiros-Tejeira - Multivisceral TransplantationPaul Wales - Surgical Management in Short Bowel SyndromeValeria Cohran & Conrad Cole - Racism in MedicineSend us Fan MailSupport the showThis episode may be eligible for CME credit!  Once you have listened to the episode, click this link to claim your credit.  Credit is available to NASPGHAN members (if you are not a member, you should probably sign up).  And thank you to the NASPGHAN Professional Education Committee for their review!As always, the discussion, views, and recommendations in this podcast are the sole responsibility of the hosts and guests and are subject to change over time with advances in the field.Check out our merch website!Follow us on Bluesky, Twitter, Facebook and Instagram for all the latest news and upcoming episodes.Click here to support the show.

Donner "pour" donner et sans contrepartie. Quoi que ? Qu'en est-il du don de soi alors que notre vie s'arrête et qui est donneur/donneuse ? Pour quoi et pour qui ? Le don est échange de vie ; et la vie, échange de don."Donner c'est donner" questionne le don en partant du point de vue de l'enfant pour aller à l'autre extrémité, à la fin de vie. Sommes-nous prêts à donner notre corps à la science ou le donner pour qu'on y prélève les organes ? Delphine Salkin aborde ces questions en immersion à l'hôpital Erasme à Bruxelles en 2024 au Service des Soins Intensifs et de la Transplantation pour y suivre le don d'organes depuis le donneur jusqu'au receveur. Conjointement, elle tisse la question du don en faisant entendre la parole des enfants de huit et neuf ans rencontrés lors d'ateliers sur le don dans une école à Bruxelles.La réalisatrice fait entendre ceux et celles qui vivent le don dans leur corps (organe donné par un proche disparu et organe reçu) et les médecins qui les accompagnent. Ceux-ci nous expliquent le cadre médical et légal de la transplantation et notamment la question du don dans le cadre de l'euthanasie.Nous avons suivi la responsable du don d'organes à l'Hôpital Erasme, le Dr Leda Nobile Nous avons suivi la responsable du don d'organes à l'Hôpital Erasme, le Dr Leda Nobile.  Nous avons pu recueillir différents témoignages dont celui de Barbara, maman d'un jeune donneur et Gia qui a reçu un coeur.  Les enfants, rencontrés dans une école à Bruxelles lors d'ateliers radio-théâtre, viennent ponctuer le documentaire et ouvrir le champ de cette écoute, comme un rappel de notre début de vie et de nos rêves et espoirs.ÉQUIPE RÉALISATIONRéalisatrice et montage : Delphine SalkinCo-montage : Zoé SulikoPrises de sons : Zoé Suliko Enregistrements additionnels par Irvic d'Olivier, Delphine Salkin et Flora LoayzaMusiques : Pascale SalkinMixage : Matthieu CharrayVisuel : Sibylle LoayzaPRODUCTEURSLettres en voixContact :  info@lettresenvoix.org // Tel +32 472 61 56 43Site internet : https://www.lettresenvoix.org/Instagram : https://www.instagram.com/lettresenvoix/Coproducteurs 1/ACSR Contact : communication[at]acsr.be // Tel : + 32 2 219 23 25Site internet : https://www.acsr.be/Instagram : https://www.instagram.com/acsr.be/2/ NONUMOÏ Contact : nonumoi.creation@gmail.com // Tel + 33 7 49 93 50 43Site internet : https://nonumoi.fr/Instagram : INSTAGRAM : https://www.instagram.com/non_umoi/FACEBOOK : https://www.facebook.com/p/Nonumoï-100064727616779/AVEC LE SOUTIEN - du FACR : Fonds d'aide à la Création radiophonique de la Fédération Wallonie Bruxelles.- de l'ASBL Pierre de Lune pour les ateliers donnés à l'école A la croisée des chemins à Neder Overembeek    • de l'hôpital Erasme pour les accès ouverts à tous les services concernésIllustration : Sibylle Loayza

In a cobranded episode between Oncology on the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Mitchell E. Horwitz, MD, highlighted key developments and ongoing initiatives related to allogeneic and cord blood transplantations among patients with different hematologic malignancies. The conversation touched upon the impact of omidubicel-onlv (Omisirge) on patient outcomes, current research on reducing the risk of graft-versus-host disease (GVHD) among transplantation recipients, and strategies for providing effective prophylaxis during treatment, among other topics. According to Horwitz, omidubicel has served as an “important graft source” for pediatric patients while improving cord blood transplantation for adults since its FDA approval in April 2023 for patients 12 years and older with hematologic malignancies. He also spoke to the importance of the FDA's approval of the agent in December 2025 for patients with severe aplastic anemia and no compatible donors following reduced intensity conditioning. Regarding those with severe aplastic anemia, he noted that omidubicel may considerably improve the feasibility of cord blood as a graft source for transplantation.Beyond these approvals, Horwitz described ongoing work dedicated to reducing the risk of GVHD following cord blood-derived transplantation, citing a pilot study that he and colleagues are conducting to determine the feasibility of adding a co-stimulatory blocking monoclonal antibody to help further limit this risk. Additionally, he emphasized surveilling for viruses like Epstein-Barr virus, HHV-6, and cytomegalovirus to mitigate the risks of delayed immune recovery following transplantation.“It's important to have all these [graft sources], whether it be cord blood, mismatched family members, mismatched unrelated donors, and matched siblings…to be made available [and] studied extensively,” Horwitz concluded. “We need to find what the best niche would be for each of these graft sources and make sure that [they] are utilized at the various institutions. The nuances, such as infection prophylaxis or infection monitoring, [should become] familiar to the transplant centers. By doing that, we can continue this trend of having a graft source for everyone and improving outcomes.”Horwitz is a professor of Medicine, Hematologic Malignancies and Cellular Therapy at Duke University School of Medicine and cellular therapy and stem cell specialist at Duke Cancer Institute.References FDA approves cell therapy for patients with blood cancers to reduce risk of infection following stem cell transplantation. News release. FDA. April 17, 2023. Accessed May 20, 2026. bit.ly/3UEO3kp FDA approves first cellular therapy to treat patients with severe aplastic anemia. News release. FDA. December 8, 2025. Accessed May 20, 2026. https://tinyurl.com/yuu377yt

Zwei engagierte Frauen, zwei bewegende Lebensgeschichten – und ein gemeinsames Ziel: anderen Menschen Mut zu machen. Dörthe Bruske und Katrin Möller leben jeweils mit einem Spenderherz und wissen aus eigener Erfahrung, wie zerbrechlich das Leben sein kann. Katrin Möller erkrankt bereits als Kind an Blasenkrebs. Die Folgen der Chemotherapie führen Jahre später zu einem schweren Herzfehler. 2019 kann nur eine Transplantation ihr Leben retten. Auch Dörthe Bruskes Weg ist von Krankheit geprägt: Was zunächst harmlos beginnt, entpuppt sich als Sarkoidose – eine seltene Entzündungserkrankung, die ihr Herz zunehmend angreift. Am 24. Dezember 2024 erhält sie ein Spenderorgan – ihr wohl größtes Weihnachtsgeschenk. Kennengelernt haben sich die beiden Transplantierten über Instagram. Aus dem digitalen Austausch entsteht eine enge Verbindung – und schließlich eine gemeinsame Initiative: In Hamburg gründen sie einen Stammtisch für Herz- und Lungentransplantierte sowie Wartende. Bei 3nach9 sprechen Dörthe Bruske und Katrin Möller über ihren persönlichen Weg zurück ins Leben und darüber, wie sie mit ihrer Geschichte anderen Betroffenen Kraft schenken wollen.

Im Mai 2022 hat die Schweizer Stimmbevölkerung der erweiterten Widerspruchslösung zugestimmt. Das heisst: wir alle sind Organspenderinnen und Organspender, ausser wir halten in einem Online-Register das Gegenteil fest. Doch dieses Register gibt es auch vier Jahre nach der Abstimmung noch nicht. Doch was bedeutet es, den Entscheid der Organspende für eine andere Person zu fällen? Wie haben sich die Transplantationszahlen und Wartezeiten seit der Abstimmung entwickelt? Wie funktioniert so eine Transplantation überhaupt? Und wie fühlt es sich an, wenn ein fremdes Herz in der eigenen Brust schlägt? Alle Seiten einer Herztransplantation In einer Spezialfolge vom Podcast «Gesprächsstoff» sprechen Moderatorin Sibylle Hartmann und Kaspar Keller, freier Journalist, mit einer Mutter, dessen zweijährige Tochter zur Organspenderin wurde und vier Menschen das Leben rettete. Herzchirurginnen und -chirurgen des Inselspitals gewähren einen exklusiven Einblick in eine Herztransplantation – von der Entnahme in einem anderen Spital über die Fahrt mit Blaulicht in die Insel bis zum Herzschlag beim Empfänger. Und ein 27-jähriger Berner, der vor drei Jahren ein neues Herz erhalten hat, erzählt, wie sich sein Alltag seither entwickelt hat. Moderation und Produktion: Sibylle Hartmann und Kaspar Keller Drei Artikel zur Widerspruchslösung Die Organspende: «Es war ein riesen Glücksgefühl, dass Aliena diesen Kindern ein neues Leben schenken konnte» Die Transplantation: Sie halten Herzen in ihren Händen: Ein Tag im Leben eines Transplantationsteams Das fremde Herz: Neues Organ, neue Probleme: Was nach der Transplantation kommt 3 für 1: Lesen Sie drei Monate, bezahlen Sie nur einenGefällt Ihnen unser «Gesprächsstoff» Podcast? Entdecken Sie dann die besten Recherchen und Hintergründe unserer Journalist:innen. Speziell für Sie haben wir das ‘3 für 1' Angebot konzipiert: 3 Monate lesen, nur 1 Monat bezahlen. Gute Lektüre und viel Spass.https://info.tamedia.ch/gespraechsstoffHabt ihr Feedback, Ideen oder Kritik zu «Gesprächsstoff»? Schreibt uns an podcast.bern@tamedia.ch Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In dieser Folge sprechen wir über das ALPPS-Verfahren und seine Rolle in der Behandlung kolorektaler Lebermetastasen im Vergleich zur Lebertransplantation. Wir diskutieren Indikationsstellung, Chancen und Limitationen dieses Ansatzes und ordnen die aktuelle Studienlage ein. Gast: Prof. Roland CronerModeration: Sophie HeislerBesprochene Publikation:Serenari M, Lanari J, Dueland S, Ettorre GM, Aldrighetti L, Vivarelli M, Di Benedetto F, Pinelli D, Mazzaferro V, Massani M, Ferrero A, Grazi GL, Cillo U, Jovine E, Cescon M, Line PD; ALPPS Italian Registry. Liver Transplantation Versus ALPPS for Colorectal Liver Metastases: An Entropy Balanced Retrospective Analysis. Ann Surg. 2026 Mar 1;283(3):357-364. doi: 10.1097/SLA.0000000000006899. Epub 2025 Aug 8. PMID: 40778636.

ASOPRS Website: Click Here Host: Deepak Ramesh In this episode of the ASOPRS Oculofacial Podcast, host Dr. Deepak Ramesh is joined by Drs. Gary Linkov and Mike McCracken to explore the evolving role of hair transplantation within oculoplastic surgery. From foundational principles like androgenetic hair loss and donor site selection to advanced techniques such as FUE vs. FUT, eyebrow restoration, and patient selection, the discussion blends science, artistry, and real-world practice insights. Whether you're considering incorporating hair restoration into your practice or simply want to better understand its nuances, this episode delivers practical pearls, business considerations, and future-forward perspectives on this growing subspecialty    

In this episode of Cancer Registry World, we are joined by Michael J. Ferguson, MD, Division Chief of Hematology, Oncology, and Stem Cell Transplantation at the University of Louisville School of Medicine, and Chief of the Norton Children's Cancer Institute in Louisville.  Dr. Ferguson shares his perspective on the critical role of pediatric cancer registries, particularly their impact on the development and success of clinical trials in pediatric oncology. We hope you enjoy this important conversation.

Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Somaya Zahran to discuss the key articles of the May issue of the American Journal of Transplantation. Somaya Zahran is a transplant nephrology fellow at the Mayo Clinic in Rochester. [03:06] Sensitization in organ transplantation: Assessment of Risk (STAR) 2025 meeting group report [08:55] The Banff 2024 Kidney Meeting Report: Rejection as a spectrum of phenotypes and focus on differential diagnostic reasoning [22:17] Normothermic versus hypothermic machine perfusion in kidney transplantation: A randomized controlled trial [27:36] Gene-edited pig cardiac xenotransplantation as a bridge to allotransplantation in infants: Progress in a pig-to-baboon model

In a special cobranded episode between Oncology On the Go, hosted by CancerNetwork®, and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, host Rahul Banerjee, MD, FACP, spoke with colleague Hitomi Hosoya, MD, PhD, about a study she and coauthors published in Blood. In their study, Hosoya and colleagues assessed the underlying mechanisms of CAR T-cell–related lymphomas developing in the gastrointestinal tract. The study focused on a particular case involving a 50-year-old patient with relapsed/refractory multiple myeloma who developed T-cell lymphoma after receiving cellular therapy in the seventh-line setting. The discussion began with an overview of the patient's treatment course, who initially responded well to seventh-line CAR T-cell therapy and experienced grade 1 cytokine release syndrome with no neurotoxicity. Two months after initiating this line of therapy, the patient experienced diarrhea and subsequent hospitalization. Following multiple endoscopies and the use of steroids and other biologic agents, the patient's diarrhea persisted, which resulted in notable weight loss and cachexia. A biopsy revealed that the patient had developed T cell infiltration in the small intestine, which correlated with an eventual diagnosis of T-cell lymphoma. After the patient's diagnosis, Hosoya outlined her team's decision to administer cyclosporine to help mitigate and eventually resolve the patient's diarrhea. Beyond this symptom management, she highlighted the challenges of treating those with GI-related T-cell lymphomas based on a lack of sufficient treatment protocols and clinical experience across the country. Overall, she emphasized teamwork as an essential component of managing and further understanding CAR T-cell lymphomagenesis.Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center and a member of the ASTCT Content Committee. Hosoya is a principal investigator in Hematology & Cellular Therapy at Cedars-Sinai Medical Center and an instructor of Blood and Marrow Transplant and Cellular Therapy at Stanford University.ReferenceHosoya H, Bastidas Torres AN, Fernandez-Pol S, et al. Long-term follow-up of gastrointestinal CAR T-cell lymphoma: homing, clonal expansion, and response to cyclosporine. Blood. 2026;147(11):1191-1198. doi:10.1182/blood.2025031423

In this episode of Critical Care Time, we tackle one of the most complex and high-stakes corners of critical care: the lung transplant patient in the ICU. From evaluating candidates at the edge of respiratory failure to managing the crashing post-transplant patient, we break down the practical bedside decisions that matter most — including bridge strategies, hemodynamics, immunosuppression, infection, rejection, and the complications that can rapidly spiral if you miss them. Whether you work in a transplant center or occasionally inherit these patients in a general ICU, this episode is built to give you a sharper framework, clearer priorities, and more confidence when the stakes are highest. As is often the case, a heavy lift like this needs some back up and we are grateful to have Dr. Lara Jones, a transplant pulmonologist and her colleague, Dr. Jason Gauthier, a thoracic surgeon on to help us with this one!Thank you to Integration Health for sponsoring this episode. Integration Health is committed to supporting ECMO programs through high-fidelity training, start-up support and dynamic staffing assistance when you need it the most! Check them out at www.Integration.Health! Hosted on Acast. See acast.com/privacy for more information.

Medical breakthroughs often arrive faster than our moral vocabulary can keep up.Samantha speaks with Andrew Kubick of the National Catholic Bioethics Center about uterine transplantation — from its therapeutic promise for women experiencing infertility to the profound ethical questions raised as reproductive technology expands toward increasingly experimental possibilities.When medicine gains the power not only to heal but to redesign reproduction, how should we think about human dignity, motherhood, and the meaning of the body itself?In this episode:The science and ethics of uterine transplantsTherapeutic medicine vs. technological expansionBioethics and Catholic moral reasoningThe cultural implications of redefining reproductionBuy the book:Transplanting the WombSubscribe to the newsletter!

Send us Fan MailIn this episode of Causes or Cures, Dr. Eeks sits down with transplant surgeon and author Dr. Josh Mezrich to talk about xenotransplantation—the use of animal organs, primarily from pigs, to try to address the massive shortage of human donor organs.More than 100,000 people in the U.S. are currently waiting for a transplant. For many, time runs out. Xenotransplantation offers a possible path forward, but it's not a simple one.This conversation walks through both sides.We talk about the history—from early, controversial experiments using primates to today's gene-edited pig organs—and what's actually happening right now in human patients. But we also spend time on the part that often gets pushed aside: the ethical questions.What are we asking of these animals?How are they treated in the process?And how do we weigh that against the possibility of saving human lives?We discuss:• The evolution of xenotransplantation and key scientific breakthroughs• Real-world cases of patients receiving pig organs• The role of CRISPR and genetically engineered pigs• Ethical concerns around animal welfare and the use of nonhuman primates in research• Whether focusing on animal organs shifts attention away from improving human organ donation systems• The risks, including cross-species disease transmissionDr. Mezrich also shares insights from his new book Every Living Creature, which explores both the promise and the discomfort of this field.Dr. Mezrich is a transplant surgeon and Professor at the University of Wisconsin, where he holds the Mark A. Fischer Chair in Transplantation and serves as Surgical Director of the kidney transplant program. His clinical and research work focuses on liver and kidney transplantation, including how factors like the microbiome and biomarkers influence organ quality. He is also the author of How Death Becomes Life and his latest book, Every Living Creature, which explores the science and ethics of xenotransplantation. Work with me? Perhaps we are a good match. Keep Causes or Cures Ad-Free with Listener SupportYou can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Follow Public Health is WeirdOr Facebook here.On Youtube.Or TikTok.SUBSCRIBE to her Newsletter here! (the bits not posted on socia media)Support the show

Forschende weltweit suchen nach Lösungen, denn die Zahlen sind bedrückend und zeichnen ein Bild der stillen Verzweiflung: Jedes Jahr stehen in Deutschland tausende Menschen auf der Warteliste für ein Spenderorgan. Allein auf eine Niere warteten in den vergangenen Jahren konstant mehr als 6.000 Patient*innen. Dem gegenüber stehen aufgrund fehlender Spenderorgane nur etwa 1.500 Transplantationen. Die Lücke hat unerbittliche Folgen: Jahr für Jahr sterben hunderte Menschen, weil für sie kein passendes Organ zur Verfügung steht. Einer der Lösungsansätze ist eine Forschungs- richtung, die lange weniger nach Science und mehr nach Fiction klang, nun aber greifbare Realität wird: die Xenotransplantation. Hintergründe zu dieser Art von Forschung liefert der Kompass 2026 auf den Seiten 21 bis 24. Harte öffentliche Kritik von Tierschützern Können sie für Entspannung im Rennen um Spenderherzen sorgen? Schweinherzen, die in Menschen verpflanzt werden, können für Herzkranke die letzte Hoffnung sein- die Warteliste für ein neues Spenderherz ist lang. Aber: Die Spender-Organe werden durch genetische Anpassungen immer verträglicher, erste Übertragungen auf Menschen sind erfolgt. Neben unterschiedlichen Strategien, die Organe an den menschlichen Körper anzupassen, nimmt die ethische Debatte zunehmend an Fahrt auf: Darf den Tieren das Herz entnommen werden? Auf dem Weg zur Transplantation in Menschen war es ein langer Weg. Herzen wurden in Paviane verpflanzt. Damit zeigten die Forscher zum ersten Mal, dass die Übertragung eines Organs über Artgrenzen hinweg möglich ist und das übertragene Organ die Funktion übernimmt. Anubispavian-Weibchen am Deutschen Primatenzentrum in Göttingen. Foto: Karin Tilch/DPZ. 10 Fakten zu Schweinen Mit dem Thema Xenotransplantation befasst sich auch unser Podcast „Fabeln, Fell und Fakten S3E5.

Michael chats with Jaya Tiwari, Senior Vice President of Global Medical Affairs at XVIVO. Together, they discuss today's organ transplant ecosystem, how organ transplants and preservation technology have evolved over time, remaining significant gaps between organ supply and demand and the transplant system, how XVIVO is expanding access and improving patient care in transplantation, what could be next for the organ transplant landscape, and much more.  Learn more about XVIVO at www.XVIVOGroup.com.

AJT April 2026 Editors' Picks Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Cesar Berto to discuss the key articles of the April issue of the American Journal of Transplantation. Dr. Cesar Berto is an Assistant Professor at the University of Alabama, Birmingham, in the Division of Infectious Diseases [03:28] Invasive mold infection in heart transplant recipients: A nationwide multicenter matched case–control study between 2008 and 2022 in France [08:50] Pharmacokinetics, lineage identity, and trafficking of ex vivo expanded polyclonal regulatory T cells in a prospective randomized clinical trial of kidney transplant recipients with allograft inflammation [20:55] Transmembrane protein 16F-chloride intracellular channel 1 interaction mediates recipient dendritic cell cross-decoration after transplantation [31:27] Dual costimulation blockade with the CD154-specific fusion protein dazodalibep and belatacept for prophylaxis of kidney allograft rejection [43:52] Costimulatory blockade and infectious risk in solid organ transplantation

We're almost a month into autumn and there's a definite nip in the air which means that flu season - and the flu shot - isn't far away. Maybe you'll also be thinking about whether or not to get a COVID booster. But imagine if there was one vaccine that could protect you against both of those - and more. Well a recently published American study suggests that a universal vaccine may very well be possible. Dr Bali Pulendran is a Professor at Standford University's School of Medicine, Director of its Institute for Immunology, Transplantation and Infection and senior author of the study. He talks to Susie Ferguson about what this could mean in the face of another global pandemic.

Send us Fan MailIn this episode, we discuss an overview of lung transplantation, from the process itself to the associated medications and potential complications. Written by: Dr. Yi Tao Chan. Reviewed by Dr. Ciaran Scallan and John Neary.Support the show

"You want to try to act quickly and be able to know what the pathways are for appropriate escalating when a patient is having symptoms that are reflective of cytokine release syndrome (CRS) or neurotoxicity. These toxicities are very manageable and treatable when recognized early. To summarize, choosing the right patient, knowing the toxicity profile for each product, and acting early is really what helps to prevent severe outcomes with chimeric antigen receptor (CAR) T-cell therapy," Maribel Pereiras, PharmD, BCPS, BCOP, clinical pharmacy specialist at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about CAR T-cell immunotherapy. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 20, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to CAR T-Cell immunotherapy in the treatment of cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 267: Side-Effect Management for CAR T-Cell Therapy for Hematologic Malignancies Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation Episode 176: Oncologic Emergencies 101: Cytokine Release Syndrome ONS Voice articles: A Body of Evidence Helps Nurses Manage CAR T-Cell Therapy Toxicities CAR T-Cell Therapy Programs Oncology Clinical Social Workers Add Layers of Support for Patients and Families During CAR T-Cell Therapy Studies Show Best Practices to Manage CAR T-Cell Therapies' irAEs and Improve Outcomes ONS Voice oncology drug reference sheet: Lisocabtagene Maraleucel Clinical Journal of Oncology Nursing articles: CAR T-Cell Therapy for Relapsed/Refractory Aggressive Large B-Cell Lymphoma CAR T-Cell Therapy: Updates in Nursing Management Nursing Considerations in Navigating Patients Receiving CAR T-Cell Therapy ONS book: Guide to Cancer Immunotherapy (second edition) ONS Huddle Cards: Chimeric Antigen Receptor T-Cell Therapy Cytokine Release Syndrome Immune Effector Cell–Associated Neurotoxicity Syndrome Immunotherapy Immuno-Oncology Learning Library American Society of Gene and Cell Therapy: Learning Center American Society for Transplantation and Cellular Therapy: Learning Center National Comprehensive Cancer Network home page To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "CAR T-cell therapy combines an adoptive cell transfer with genetic engineering. And what that really means is that we are harvesting a patient's own T cells and then we engineer them with a synthetic receptor that helps them recognize that cancer. And all of this work has evolved through many decades of stepwise advances in how we design and activate the T cells. That led us to several landmark trials and ultimately the first CAR T-cell therapy approved by the U.S. Food and Drug Administration in 2017, which was tisagenlecleucel for pediatric and young adult patients that had acute lymphoblastic leukemia." TS 3:34 "If a patient has higher disease burden or an inflammatory biology, that does tend to correlate with higher toxicity risk. And then that might influence the way we monitor the patients who are getting the CAR T therapy. And then finally, baseline neurologic examinations, because neurotoxicity can occur with these agents. It's very important that we as a whole healthcare team really understand what the patient looks like at baseline to be able to determine if they're having any altered changes or confusion. If I had to summarize it, we want to confirm the target and make sure that we have the right CAR T product for the patient. We want to confirm that the patient, physiologically and mentally, is ready for the CAR T therapy." TS 10:53 "I think the two [toxicities] that every nurse will hear about almost immediately when talking about CAR T therapy are CRS or ICANS, which stands for immune effector cell–associated neurotoxicity syndrome. ... ICANS can either follow or even occur alongside CRS. And this can present as something as simple as just being slightly confused or altered, leading into progressively more severe elements such as word-finding difficulties, tremors, or changes in handwriting. Or even more severe cases that lead to seizures or decreased levels of consciousness. So, in this setting, neurologic assessments and knowing and understanding what your patient's baseline neurologic status is is so important. Those are really the two largest side effects that cross the board when it comes to CAR T therapies." TS 16:02 "In terms of the more practical aspects of administration, this is not a typical medication infusion. CAR T cells are living cells. So the way they are handled and administered is very specific. The majority of CAR T products are given as a single IV infusion. The cells come to us frozen either from a cellular lab or they will come from the pharmacy department. So those cells are typically thawed, and timing is of the essence. You really need to coordinate the timing of [thawing] to when they get infused to your patient. They tend to have a short shelf life once they're not frozen anymore." TS 26:34 "Now that therapy has, in many places, transitioned to be administered in the outpatient setting, education becomes absolutely critical. The patient is coming for their daily visit to clinic and then they're going home. And it's really up to the caregiver, who is usually not a nurse, who has to recognize early signs of toxicity. They need to be educated about what a fever is, what number constitutes a fever, what does confusion look like, what does hypotension look like? ... Do they have access to a thermometer? If you are asking them to look at blood pressure, do they have access to a blood pressure monitor? And sometimes those can be subtle things that might be overlooked. So, the emphasis in outpatient quality education is teaching those caregivers what to watch for, how to act quickly, and who to call immediately. You need to make sure that they have that information readily available if something happens." TS 30:55

This week Clarence Ford and Dr Chris discuss NASA's DART mission to defect an asteroid, why we can't tickle ourselves, whether lung capacity affects the heart, if white skin transplanted to a black person changes colour, why some people are more ticklish than others, how scientists are able to read ancient DNA codes, why the sea is salty, and what triggers seizures? Like this podcast? Please help us by supporting the Naked Scientists

This week Clarence Ford and Dr Chris discuss NASA's DART mission to defect an asteroid, why we can't tickle ourselves, whether lung capacity affects the heart, if white skin transplanted to a black person changes colour, why some people are more ticklish than others, how scientists are able to read ancient DNA codes, why the sea is salty, and what triggers seizures? Like this podcast? Please help us by supporting the Naked Scientists

Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Justin Barr to discuss the key articles of the March issue of the American Journal of Transplantation. Justin Barr practices abdominal transplant and advanced hepatobiliary surgery at Ochsner Medical Center [03:13] Implementation of a physician assistant-led recovery model for heart transplantation: Clinical outcomes and programmatic benefits at a high-volume center [13:54] A 100-year simulation of the National Kidney Registry's voucher program [25:32] Risk of deficient mismatch repair colorectal cancer and precursors after kidney transplantation: A nationwide study [35:09] Predictive value of torque teno virus viral load for BK polyomavirus DNAemia depends on BK polyomavirus–specific humoral immunity in kidney transplant recipients [42:50] Suppression of cardiac allograft vasculopathy by a macrophage efferocytosis receptor

This week we speak with Dr. John Brown who is the Harris B. Schumacker Professor Emeritus of Surgery at the University of Indiana. A congenital heart surgeon for over 45 years, Dr. Brown has performed more than 15,000 pediatric heart operations at Riley Hospital for Children and another 5000 heart operations in adults at IU and Methodist Hospitals. He performed the first pediatric heart transplant in Indiana and developed the first clinical use of the bovine jugular vein and valve for a pulmonary valve replacment in children. He also performed the only known twin to twin newborn heart transplant in the world. He has done and seen it all and has a unique perspective. How did he achieve so much and still have a succesful 56 year marriage to his wife Carol Ann? What is Dr. Brown most proud of in a career that is as prolific as his? What advice would he have have for the next generation? Prepare to be inspired by this master surgeon and friend and colleague of many in our field.

Last time we talked about kidney xenotransplantation, we were joined by Towana Loony and Tim Andrews, who shared their personal experiences with receiving a xenotransplant. Today, two doctors who helped propel xenotransplantation forward, Dr. Vineeta Kumar and Dr. Leonardo Riella, are here to explain the science and what comes next. This episode is supported by eGenesis and United Therapeutics In this episode we heard from:  Vineeta Kumar is the lead nephrologist for UAB's Living Kidney Donor and Incompatible Kidney Transplant programs. She is an expert in kidney transplantation, living kidney donation, incompatible kidney transplant, kidney paired donation and cardiovascular outcomes after kidney transplantation. Kumar also engages in research in the prevention, treatment and prognosis of antibody mediated rejection. She has been named a "Top Doctor" by U.S. News & World Report each year since 2012. She has been lead facilitator of the UAB Schwartz Rounds since 2009, a program that brings together nurses, physicians, social workers, and other providers to discuss delivery of compassionate care. She was awarded the Brewer-Heslin Endowed Award for Professionalism in Medicine for the highly skilled and compassionate medical care she provides to her patients. Kumar was recently named "Best Educator" by the 2018, 2019 and 2020 UAB Medical School classes. She has previously served on the Education Committee for the American Society of Transplantation. Leonardo V. Riella, M.D., Ph.D. is the Harold and Ellen Danser Endowed Chair in Transplant Surgery at Harvard Medical School and the Medical Director of Kidney Transplantation at Massachusetts General Hospital. His research focuses on mechanisms of immune regulation and the development of novel therapies to promote transplant tolerance. In addressing kidney disease recurrence post-transplantation, he founded and leads the TANGO Consortium, the largest global effort dedicated to studying glomerular disease recurrence. In March 2024, Dr. Riella led the world's first successful kidney xenotransplant from a gene-edited pig into a living human. He now leads the first FDA-approved pilot study in kidney xenotransplantation and is conducting high-dimensional immune profiling studies to characterize the human xeno-immune response and guide immunosuppressive strategies. Find out more about Dr. Riella's research here.     Additional Resources Xenotransplantation Information   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

Mary Roach explores the future of 3D-printed organs, explaining how researchers use specialized ink and support gels to recreate complex structures like heart muscles for transplantation. 2

This study of 801 multiple myeloma patients found that atrial fibrillation occurred in 5.5% within 90 days after autologous stem cell transplantation—nearly double previously reported rates—indicating disease‑specific risks. AF strongly predicted mortality from non‑relapse causes and may serve as a marker of physiological vulnerability, emphasizing the value of expanded pre‑transplant cardiac assessment and monitoring.

Was ist Schönheit?; Niedrigwasser in der Ostsee; Wie Social Media Jugendliche in den Bann zieht; Alternative Soziale Medien; Neue Erdölfördergebiete in Brasilien; Maschinenperfusion - Neue Hoffnung in der Organspende; Moderation: Marija Bakker. Von WDR 5.

At the 2026 Tandem Meetings, CancerNetwork® spoke with a variety of experts who presented on key developments and advancements across hematologic oncology. As part of different oral presentations and poster sessions, researchers and clinicians shared updated findings that may influence the management of myelodysplastic syndromes (MDS), leukemia, lymphoma, and other blood cancer types.First, Fernando Duarte, head of the Bone Marrow Transplant Service at Walter Cantídio University Hospital (HUWC), hematologist and professor at the Federal University of Ceará, and president of the Brazilian Society of Cell Therapy and Bone Marrow Transplant, highlighted his presentation analyzing trends associated with allogenic hematopoietic cell transplantation (allo-HCT) among patients with MDS or myeloproliferative neoplasms (MPN) and other types of MDS. Data from the Brazillian SBTMO and CIBMTR registry revealed that patients receiving allo-HCT for MDS/MPN were typically older with worse performance statuses. Additionally, MDS/MPN independently predicted worse overall survival (OS) and relapse-free survival outcomes.Next, Alfonso Molina, MD, MPH, a third-year Hematology and Medical Oncology fellow at Stanford University, detailed results from a phase 1 trial (NCT05507827) assessing Orca-T, an investigational allogeneic T-cell immunotherapy, among those with high-risk B-cell acute lymphoblastic leukemia (B-ALL). Treatment with Orca-T yielded disease-free survival and OS in all (100%) 18 evaluable patients after a median follow-up of 14 months (range, 3-35), which occurred without graft failure, significant graft-versus-host-disease, or severe CAR-mediated toxicity.Finally, Irtiza N. Sheikh, DO, an assistant professor in the Department of Pediatrics - Patient Care, Stem Cell Transplantation and Cellular Therapy Section of the Division of Pediatrics at The University of Texas MD Anderson Cancer Center, discussed his presentation exploring differences in outcomes with lisocabtagene maraleucel (Breyanzi; liso-cel) across various treatment settings and patient populations with large B-cell lymphoma. Data demonstrated that among patients younger than 50 years old, liso-cel produced enduring responses across real-world and clinical trial settings, which were comparable to outcomes in overall populations. References Duarte FB, Garcia YDO, Hamerschlak N, et al. Comparative outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and other myelodysplastic syndromes: Brazilian Sbtmo/CIBMTR registry analysis. Presented at: 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR; February 4-7, 2026; Salt Lake City, UT. Presentation 63. Molina A, Shiraz A, Kanegai A, et al. Mature outcomes from the phase I trial of Orca-T and allogeneic CD19/CD22 CAR-T cells for adults with high-risk B-ALL. Presented at: 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR; February 4-7, 2026; Salt Lake City, UT. Presentation 31. Sheikh IN, Patel K, Perales MA, et al. Clinical outcomes of lisocabtagene maraleucel (liso-cel) in YOUNGER PATIENTS (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). Presented at: 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR; February 4-7, 2026; Salt Lake City, UT. Poster 210.

A heartfelt memoir about the search for religion and identity “I'm not Jewish.” For years, that's what David Weill told anyone who asked about his religious background. Yes, his father was a Jew who had left Nazi Germany as a boy. But his mother was a Southern Baptist. Growing up in New Orleans, religion wasn't something his family discussed, let alone practiced. As an adult, he developed a fervent zeal and profound devotion to his work as a specialist in organ transplants. Transplantation was all he needed to define and fulfill him—until a crisis shook him to the core. In 2015, after the simultaneous unraveling of his carefully crafted career and the death of his father, Weill began to doubt everything, including his purpose in life. While grappling with emotional pain and sinking deeper into despair, he began to suffer perplexing physical symptoms. In his moment of crisis, he was seized by a strong desire to practice a formal religion. But for Weill, the real question was, Which religion? Eventually, he chose Catholicism and was baptized at age fifty. He found solace in heart-to-heart talks with a priest and his daughters' happiness at having the whole family at church together. Everything was fine—until 2020, when he learned that his mother had converted to Judaism right before marrying his father. He was born a Jew. And in the eyes of the Jewish faith, he would always be Jewish. That realization sparked his second quest. Become a supporter of this podcast: https://www.spreaker.com/podcast/arroe-collins-unplugged-totally-uncut--994165/support.

Invité, fonction, était l'invité de François Sorel dans Tech & Co, la quotidienne, ce jeudi 24 septembre. Il/Elle [est revenu(e) / a abordé / s'est penché(e) sur] [SUJET] sur BFM Business. Retrouvez l'émission du lundi au jeudi et réécoutez la en podcast.

In this episode of JHLT: The Podcast, the Digital Media Editors host a discussion on a new consensus statement from ISHLT on Short Telomere Syndrome (STS) and Lung Transplantation. The document was first published last month. They're joined by document leads Andrew Courtwright, MD, PhD, of the University of Pennsylvania in Philadelphia; Dr. John Mackintosh of Prince Charles Hospital in Brisbane; and John McDyer, MD, of the University of Pittsburgh Medical Center in Pittsburgh. The conversation includes discussion of: Recommendations for assessing patients for STS Which patients we should screen How the diagnosis influences transplant decision making and risk assessment How STS impacts immunosuppression Extrapulmonary comorbidities Future areas for research ISHLT Standards, Guidelines, and Consensus Statements are open to all at ISHLT.org. For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt. Return later this month for a conversation on barriers and opportunities in utilizing DCD hearts in transplantation. Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Juan Pablo Huidobro to discuss the key articles of the February issue of the American Journal of Transplantation. Juan Pablo Huidobro is an Assistant Professor in Nephrology at Pontifical Catholic University of Chile [02:52] Evolving landscape of thrombotic microangiopathy in kidney transplant recipients in the post–C5 inhibitor era [13:22] Erythropoietin prolongs graft survival in mice by counteracting trained immunity [22:06] A new principle to attenuate ischemia reperfusion injury in kidney transplantation [33:14] Sustained allogeneic kidney graft operational tolerance despite discontinued conventional immunosuppression after CD19-CAR-T-cell therapy for relapsed/refractory post-transplantation lymphoproliferative disorder [40:15] Bloodstream Infection Subtypes and Characteristics Comparing Solid Organ Transplant and Non-Transplant Populations

Andrew Jacques, Giuliano Testa, Massimo Mangiola, Liza Johannesson. Uterus Transplantation—Current Evaluation, Monitoring, and Emerging Diagnostics. Clinical Chemistry, Volume 72, Issue 1, January 2026, Pages 18–26. https://doi.org/10.1093/clinchem/hvaf143

Dr. Michael Cooper, Chief of Transplantation at the Medical College of Wisconsin and Chair of the Board of Directors for Donate Life America, shares his perspective on recent media coverage, its impact on the organ donor registry, and what the media is missing about organ transplantation.

Rural Health News is a weekly segment of Rural Health Today, a podcast by Hillsdale Hospital. News sources for this episode: Jared Ortaliza, “ACA Signups are Down, But Still an Incomplete Picture,” January 12, 2026, https://www.kff.org/quick-take/aca-signups-are-down-but-still-an-incomplete-picture/, KFF. Sam Gringlas, “House votes to renew ACA subsidies, as Senate Republicans rebuke Trump on Venezuela,” January 8, 2026, https://www.npr.org/2026/01/08/nx-s1-5662625/house-vote-affordable-care-act-subsidies, National Public Radio. America's Health Rankings, “2025 Annual Report,” 2025, https://assets.americashealthrankings.org/ahr_2025annual_comprehensivereport_final-web.pdf.  Elizabeth Gregerson, “Northwestern takes on its biggest rival in transplants: Time,” January 9, 2026, https://www.beckershospitalreview.com/quality/patient-safety-outcomes/northwestern-takes-on-its-biggest-rival-in-transplants-time/, Becker's Hospital Review. Mackenzie Bean, “Nation's 1st double lung-liver transplant performed at Northwestern,” March 28, 2024, https://www.beckershospitalreview.com/quality/patient-safety-outcomes/nations-1st-double-lung-liver-transplant-performed-at-northwestern/, Becker's Hospital Review. American Lunch Association, “Lung Transplant,” December 10, 2025, https://www.lung.org/lung-health-diseases/lung-procedures-and-tests/lung-transplant. Tanmay S. Panchabhai et al., “Historical perspectives of lung transplantation: connecting the dots,” July 31, 2018, https://jtd.amegroups.org/article/view/22674/html, Journal of Thoracic Disease. Rural Health Today is a production of Hillsdale Hospital in Hillsdale, Michigan and a member of the Health Podcast Network. Our host is JJ Hodshire, our producer is Kyrsten Newlon, and our audio engineer is Kenji Ulmer. Special thanks to our special guests for sharing their expertise on the show, and also to the Hillsdale Hospital marketing team. If you want to submit a question for us to answer on the podcast or learn more about Rural Health Today, visit ruralhealthtoday.com.

In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD(The University of Texas MD Anderson Cancer Center; Pharmacy SIG Immediate Past-Chair), sits down with Zainab Shahid, MD (Memorial Sloan Kettering Cancer Center; ID SIG Chair), and Gabriela Maron, MD (St. Jude Children's ResearchHospital). As coauthors of the ASTCT Practice Guidelines, "American Society for Transplantation and Cellular Therapy Best Practice Considerations for the Prevention and Management of Infections After Chimeric Antigen Receptor T-Cell Therapy for Hematological Malignancies," recently published in Transplantation and Cellular Therapy, they discuss the implementation of critical strategies for safeguarding CAR T recipients.The conversation explores the nuances of the manuscript,providing a practical perspective on translating these consensus recommendations into clinical operations.Assessing the Burden of Immunosuppression: Evaluating the cumulative risk factors that predispose CAR T recipients to infection, including heavy pretreatment and the effects of lymphodepletion.Prophylaxis Optimization: Critical considerations regarding the timing, selection, and duration of antimicrobial regimens in the post-CAR T setting.Managing Hypogammaglobulinemia: A pragmatic look at IVIG replacement strategies, balancing emerging clinical evidence with institutional protocols and global product shortages.Addressing Evidence Gaps: Insider insights into the expert panel's deliberations on "grey areas," such as the management of CMV reactivation and optimal post-therapy vaccination schedules.The Pediatric-Adult Continuum: Ensuring that prevention and management strategies are robust and applicable across the full age spectrum of CAR-T recipients.This episode provides essential context for cliniciansseeking to move beyond the published guidelines and operationalize these bestpractices with greater precision and confidence.Thank you to Johnson & Johnson and Legend Biotech forsupporting this episode.

In a special cobranded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Rahul Banerjee, MD, FACP, a physician-researcher who specializes in multiple myeloma at Fred Hutchinson Cancer Center, and Brooke Adams, PharmD, BCOP, a clinical pharmacist and transplant specialist at Orlando Health, break down practice‑changing data in multiple myeloma from the ASH Annual Meeting.The experts focus on bispecific antibodies and BCMA CAR T-cell therapies and close the discussion by reflecting on how data is redefining the treatment paradigm in multiple myeloma, raising possibilities of deep MRD negativity, treatment de-escalation, and prolonged drug holidays. Listen below or via your favorite podcast platform.

Das neue Jahr startet mit einer prall gefüllten Wundertüte: Dr. Anne Fleck beantwortet eure Zuschriften – unter anderem dazu, was gegen starke Neurodermitis helfen kann, wo Knackpunkte bei Migräne-Schmerzen liegen und was nach einem gravierenden Eingriff wie einer Herztransplantation beachten werden sollte. +++

AJT January 2026 Editors' Picks Description:  Hosts Roz and Dr. Sanchez-Fueyo are joined by Dr. Al-Faraaz Kassam to discuss the key articles of the January issue of the American Journal of Transplantation. Al-Faraaz Kassam is an Assistant Professor in Transplant Surgery at Johns Hopkins University [03:45] Evaluation of kidney procurement biopsy and machine perfusion on allograft outcomes: A retrospective cohort study of the OPTN database [11:23] Improving the  histologic detection of donor-specific antibody-negative antibody-mediated rejection in kidney transplants [23:01] Exosome-primed T cell immunity is facilitated by complement activation [32:26] Landscape of subclinical rejection in a large international cohort of pediatric kidney transplant (kTx) recipients [42:19] Donor Heart Preservation at 10°C After Thoracoabdominal Normothermic Regional Perfusion Lowers Rates of Severe Primary Graft Dysfunction and Improves Recipient Transplant Outcomes  

Send us a textHair transplantation ~ Succeeding as a female in a Male-Dominated FieldMargaret Zakhary is a surgical PA, licensed in 9 US states. She has a family history of hair loss, with her Mum first experiencing hair loss at 16 years old, when she suffered permanent scarring from chemical damage. She tried wearing a wig for hair loss, but it looked terrible!Later on, when she was only 33, she became very ill, and Margaret, being just ten, began experiencing hair loss herself, and since has had several forms of hair loss throughout her life.She believes in turning tragedy into purpose, and shares how these events inspired her to study hair loss, to ensure that every patient has an advocate, and that they can get the care they need.Connect with Margaret:Instagram Hair & Scalp Salon Specialist course Support the showConnect with Hair therapy: Facebook Instagram Twitter Clubhouse- @Hair.Therapy Donate towards the podcast Start your own podcastHair & Scalp Salon Specialist Course ~ Book now to become an expert!

This week we go back in time 2 years to review a recent paper from 2023 about outcomes of cardiac transplantation in the adult congenital heart patient (ACHD). Little has been written on this topic until this very robust and large scale report. How do single ventricle ACHD patients fair at transplant and how do they compare to non-ACHD heart transplant recipients? Why might 1 and 3 year outcomes not be a 'fair' method of assessing outcomes in this very high risk patient group? How do HLHS patient outcomes compare with other single ventricles? Are there better ways to measure risk in this patient group and how might the data in this work inform risk stratification and management of failing Fontan patients in whom transplantation is being considered? These are amongst the questions posed this week to the week's expert, Dr Daphne Hsu who is Professor of Pediatrics at the Albert Einstein College of Medicine at The Children's Hospital at Montefiore.https://doi.org/10.1016/j.jacc.2023.06.037For those interested in learning more about Dr. Hsu, take a listen to episode #166 from June, 2021:https://www.spreaker.com/episode/pediheart-podcast-166-a-conversation-with-professor-daphne-hsu--45144274

This week on Health Matters, Courtney talks with Dr. Robert Brown, the chief of gastroenterology and hepatology at NewYork-Presbyterian and Weill Cornell Medicine, to discuss the benefits and risks of taking dietary supplements, for our liver and our overall health. Dr. Brown offers tips for deciding which supplements to take, which to avoid, and ways we can optimize our liver health. ___Dr. Robert Brown is an expert in liver diseases, including alcohol-related liver disease, which affects up to 20 percent of the population, chronic hepatitis C infection, which affects an estimated 2.4 million Americans and cirrhosis, a scarring of the liver that is the third most common disease-related cause of death in the United States. He co-founded the Center for Liver Disease and Transplantation at NewYork-Presbyterian/Weill Cornell Medical Center, a joint program with Columbia University Irving Medical Center, in 1998. Dr. Brown will continue as medical director of this program, the largest for liver transplantation in New York City.___Health Matters is your weekly dose of health and wellness information, from the leading experts. Join host Courtney Allison to get news you can use in your own life. New episodes drop each Wednesday.If you are looking for practical health tips and trustworthy information from world-class doctors and medical experts you will enjoy listening to Health Matters. Health Matters was created to share stories of science, care, and wellness that are happening every day at NewYork-Presbyterian, one of the nation's most comprehensive, integrated academic healthcare systems. In keeping with NewYork-Presbyterian's long legacy of medical breakthroughs and innovation, Health Matters features the latest news, insights, and health tips from our trusted experts; inspiring first-hand accounts from patients and caregivers; and updates on the latest research and innovations in patient care, all in collaboration with our renowned medical schools, Columbia and Weill Cornell Medicine.To learn more visit: https://healthmatters.nyp.org

CardioNerds kicks off its advanced therapies series with Chair of the CardioNerds Heart Failure Council, Dr. Jenna Skowronski, co-chair of the series, Dr. Shazli Khan, and Episode FIT lead, Dr. Jason Feinman. In this first episode, they discuss the process of advanced therapies evaluation with Dr. Michelle Kittleson, Professor of Medicine and Director of Education in Heart Failure and Transplantation at Cedars-Sinai. In this case-based discussion, they cover the signs and symptoms of end-stage heart failure, the initial management strategies, and the diagnostic workup required when considering advanced therapies. Importantly, they discuss the special considerations for pursuing left-ventricular assist device (LVAD) versus heart transplantation as well as the multidisciplinary, team-based approach needed when advanced therapies are indicated.  Notes were drafted by Dr. Shazli Khan.  Audio editing for this episode was performed by CardioNerds Intern, Julia Marques Fernandes. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Guideline-directed medical therapy (GDMT) is indicated in all heart failure patients and improves survival, but progressive symptoms and intolerance to GDMT can be warning signs of disease progression. The I-NEED-HELP mnemonic is an excellent reference when considering referral for advanced therapies (Figure).   Management of acute decompensation includes diuretics and possible inotropic support. The inotropic agent used should be whichever best suits your specific patient. Milrinone may result in more hypotension, whereas dobutamine may result in more tachycardia. Tachycardic and normotensive patients may do better with milrinone, while hypotensive patients with normal heart rates may do better with dobutamine. Notably, DoReMi found no difference between milrinone and dobutamine for patients with cardiogenic shock.  The initial diagnostic evaluation includes an echocardiogram, right heart catheterization (RHC), and often cardiopulmonary exercise testing (CPET) to objectively assess the status of the heart. Comprehensive labs, imaging and cancer screening are also needed to assess all other organs.   When making the decision to pursue advanced therapies, always ask:   Is the heart sick enough?   Is the rest of the body well enough?   These two questions provide a framework to guide if patients are optimal candidates for transplant versus LVAD.   The advanced therapies evaluation is a team sport! Patients will meet not only with advanced heart failure cardiologists, but also cardiac surgeons, psychiatrists, social workers, nutritionists and pharmacists. All team members are of critical value in the process.   Notes 1.) What are the key features of advanced cardiomyopathy, and when should providers consider referral for advanced therapies?   Advanced cardiomyopathy may present as recurrent hospitalizations for decompensated heart failure, intolerance to GDMT with symptomatic orthostasis and hypotension, and progressive symptoms of heart failure despite medical therapy.   The I-NEED-HELP mnemonic is a helpful tool to identify patients at risk of heart failure and is defined as follows: Need for Inotropic support, New York Heart Association (NYHA) Class IV symptoms, End-Organ Dysfunction, Ejection fraction

It seems like every week, there's a new headline about some kind of sci-fi-esque organ transplant. Think eyeballs, 3D-printed kidneys, pig hearts.In her new book, Replaceable You: Adventures in Human Anatomy, science writer Mary Roach chronicles the effort to fabricate human body parts—and where that effort sometimes breaks down. Host Flora Lichtman speaks with Roach about everything from hair transplants to 3D-printed hearts, and why our anatomy is so hard to replicate in the first place.Guest: Mary Roach is a science writer and the author of Replaceable You: Adventures in Human Anatomy.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

Liver transplantation continues to evolve as strategies expand to address organ shortage and optimize outcomes. Normothermic machine perfusion (NMP) offers a novel way to preserve and assess donor livers prior to implantation. In this episode of Behind the Knife, our transplant team at University of Nebraska Medical Center discusses the latest evidence from randomized trials, practical applications in donation after circulatory death (DCD) grafts, and how NMP is shaping clinical decision-making in high-risk transplants.  Hosts -  Madeline Cloonan, MD PhD, General Surgery Resident, University of Nebraska Medical Center, @maddie_cloonan   - Jacqueline Dauch, MD, Assistant Professor, University of Nebraska Medical Center  -  Shaheed Merani, MD PhD, Associate Professor, University of Nebraska Medical Center  - Alan Langnas, DO, Professor, University of Nebraska Medical Center  Learning Objectives - Describe the principles of normothermic machine perfusion (NMP) and how it differs from static cold storage.  - Summarize the design and key outcomes of the PROTECT trial and the Chapman et al. trial on NMP in liver transplantation.  - Recognize the clinical scenarios where NMP provides the greatest benefit, particularly in high-risk grafts (e.g., DCD donors, high donor risk index).  - Apply a practical viability assessment framework for livers on NMP, including hemodynamics, bile production, lactate trajectory, and histology when indicated.  - Discuss the implications of NMP for allocation, system logistics, and future adoption trends in transplantation.  References   1.     Markmann JF, Abouljoud MS, Ghobrial RM, et al. Impact of portable normothermic blood-based machine perfusion on outcomes of liver transplant: the OCS Liver PROTECT randomized clinical trial. JAMA Surg. 2022;157(3):189-198. doi:10.1001/jamasurg.2021.6781. https://pubmed.ncbi.nlm.nih.gov/34985503/ 2.     Chapman WC, Barbas AS, D'Alessandro AM, et al. Normothermic machine perfusion of donor livers for transplantation in the United States: a randomized controlled trial. Ann Surg. 2023;278(5):e912-e921. doi:10.1097/SLA.0000000000005934. https://pubmed.ncbi.nlm.nih.gov/37389552/ 3.     Nasralla D, Coussios CC, Mergental H, et al; Consortium for Organ Preservation in Europe. A randomized trial of normothermic preservation in liver transplantation. Nature. 2018;557(7703):50-56. doi:10.1038/s41586-018-0047-9. https://pubmed.ncbi.nlm.nih.gov/29670285/ 4.     Brubaker AL, Sellers MT, Abt PL, et al. US liver transplant outcomes after normothermic regional perfusion vs standard super rapid recovery. JAMA Surg. 2024;159(6):677-685. doi:10.1001/jamasurg.2024.0520. https://pubmed.ncbi.nlm.nih.gov/38568597/ 5.     Wall A, Snoddy M, Du J, et al. The current landscape of in situ and ex situ machine perfusion utilization for liver grafts from cardiac donation after circulatory death donors in the US. Am J Transplant. 2025;25(3):574-582. doi:10.1016/j.ajt.2024.09.012. https://pubmed.ncbi.nlm.nih.gov/39293517/ 6.     Watson CJE, Gaurav R, Fear C, Swift L, Selves L, Ceresa CDL, Upponi SS, Brais R, Allison M, Macdonald-Wallis C, Taylor R, Butler AJ. Predicting Early Allograft Function After Normothermic Machine Perfusion. Transplantation. 2022 Dec 1;106(12):2391-2398. doi: 10.1097/TP.0000000000004263. https://pubmed.ncbi.nlm.nih.gov/36044364/ 7.     Watson CJE, Hunt F, Messer S, Currie I, Large S, Sutherland A, Crick K, Wigmore SJ, Fear C, Cornateanu S, Randle LV, Terrace JD, Upponi S, Taylor R, Allen E, Butler AJ, Oniscu GC. In situ normothermic perfusion of livers in controlled circulatory death donation may prevent ischemic cholangiopathy and improve graft survival. Am J Transplant. 2019 Jun;19(6):1745-1758. doi: 10.1111/ajt.15241. https://pubmed.ncbi.nlm.nih.gov/30589499/ 8.     Olthoff KM, Kulik L, Samstein B, et al. Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl. 2010;16(8):943-949. doi:10.1002/lt.22091.https://pubmed.ncbi.nlm.nih.gov/20677285/  9.     Kwong AJ, Kim WR, Lake JR, Schladt DP, Handarova D, Howell J, Schumacher B, Weiss S, Snyder JJ, Israni AK. OPTN/SRTR 2023 Annual Data Report: Liver. Am J Transplant. 2025 Feb;25(2S1):S193-S287. doi: 10.1016/j.ajt.2025.01.022. https://pubmed.ncbi.nlm.nih.gov/39947804/ Ad Disclosures: Visit goremedical.com/btk to learn more about GORE® ENFORM Biomaterial. Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx only Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listen Behind the Knife Premium: General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-review Trauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlas Dominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkship Dominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotation Vascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-review Colorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-review Surgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-review Cardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-review Download our App: Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US